BiomX released FY2025 Q2 earnings on August 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1928 (forecast USD -0.26)

Brief Summary

BiomX reported a Q2 2025 EPS of -0.1928 USD and a net loss of 6.037 million USD with no revenue generated.

Impact of The News

The financial briefing from BiomX revealed that the company experienced a net loss of 6.037 million USD in Q2 2025, with an EPS of -0.1928 USD, which was better than the expected EPS of -0.26 USD. The revenue for this quarter was 0 USD, which met the market expectations.
In comparison to the previous quarter, where the company had a net income of 4.471 million USD, this quarter’s performance reflects a significant downturn Reuters. Despite the negative EPS, it still outperformed the market expectation, which might indicate better cost management or other improved financial metrics compared to projections.

The company’s net loss for Q2 2025 was influenced by a decrease in income from the change in warrant fair value TradingView. Additionally, the operating loss for the quarter was reduced to 7.433 million USD, compared to 9.725 million USD in the same quarter last year, highlighting some improvement in operational efficiency Reuters.

Considering the company’s current clinical stage and focus on developing phage therapies, the lack of revenue is consistent with its business model, which relies on successful clinical trials and subsequent commercialization phases. The significant net loss and EPS figures, however, suggest that the company is still in the early stages of development and heavily investing in research and development.

Future business development trends for BiomX will likely depend on the progress of their clinical trials and the potential for commercial partnerships or licensing agreements. Investors should closely monitor updates on these clinical milestones as they could significantly impact the company’s financial health and market valuation.